{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:17:03Z","timestamp":1697343423733},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T00:00:00Z","timestamp":1332460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology Research"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:p>The current standard of care (SoC) for chronic hepatitis C, i.e. the combination of a pegylated\u2010interferon (PEG\u2010IFN) with ribavirin (RBV), may activate underlying autoimmune conditions. Particularly, interferon (IFN) has been known to induce or exacerbate autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) in hepatitis C virus patients. We describe a severe, acute\u2010onset antimitochondrial antibody (AMA)\u2010M2 positive AIH appearing during the last weeks of SoC in a woman with chronic hepatitis C and no previous history of autoimmunity, and resolving on protracted steroids. In this context, the relevance of the characterization of the immunoglobulin isotype of portal plasma cells for a more appropriate diagnosis of autoimmune liver diseases can be emphasized.<\/jats:p>","DOI":"10.1111\/j.1872-034x.2011.00931.x","type":"journal-article","created":{"date-parts":[[2012,3,24]],"date-time":"2012-03-24T09:18:14Z","timestamp":1332580694000},"page":"428-432","source":"Crossref","is-referenced-by-count":2,"title":["Antimitochondrial antibody \u2010M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C"],"prefix":"10.1111","volume":"42","author":[{"given":"Fabio Salvatore","family":"Macaluso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Cabibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,23]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21146"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2002.37277"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90786-X"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-1-51"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90139-6"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn416"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2007.007185"},{"key":"e_1_2_4_10_2","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.3748\/wjg.v13.i32.4394","article-title":"Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg\u2010interferon\u2010alpha 2b plus ribavirin treatment","volume":"13","author":"Kogure T","year":"2007","journal-title":"World J Gastroenterol"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-002-1090-7"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02208992"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02065528"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80297-9"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05699.x"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05703.x"},{"key":"e_1_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.10.017"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22322"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280203"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP8WHR0IEVUUOJ"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2009.12.006"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2008.02.003"},{"key":"e_1_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22380"},{"key":"e_1_2_4_25_2","first-page":"221","article-title":"Clinical implications of antimitochondrial antibodies in type 1 autoimmune hepatitis: a longitudinal study","volume":"55","author":"Mishima S","year":"2008","journal-title":"Hepatogastroenterology"}],"container-title":["Hepatology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1872-034X.2011.00931.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1872-034X.2011.00931.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T01:20:08Z","timestamp":1697332808000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1872-034X.2011.00931.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,23]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1111\/j.1872-034X.2011.00931.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1872-034x.2011.00931.x","archive":["Portico"],"relation":{},"ISSN":["1386-6346","1872-034X"],"issn-type":[{"value":"1386-6346","type":"print"},{"value":"1872-034X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,23]]}}}